Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin
- 27 January 2018
- journal article
- editorial
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (6) , 1367-1368
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover studyMetabolism, 2016
- Leptin Deficiency Shifts Mast Cells toward Anti-Inflammatory Actions and Protects Mice from Obesity and Diabetes by Polarizing M2 MacrophagesCell Metabolism, 2015
- Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac FibrosisCirculation, 2015
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Cardiovascular Phenotype in HFpEF Patients With or Without DiabetesJACC, 2014
- Leptin, the sympathetic nervous system and blood pressureJournal Of Hypertension, 2014
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes MellitusCirculation, 2014
- Cardiovascular effects of leptinNature Reviews Cardiology, 2009
- Activation of the cardiac ciliary neurotrophic factor receptor reverses left ventricular hypertrophy in leptin-deficient and leptin-resistant obesityProceedings of the National Academy of Sciences, 2006
- Depot- and Sex-Specific Differences in Human Leptin mRNA Expression: Implications for the Control of Regional Fat DistributionDiabetes, 1997